Back

Alginate-chitosan hydrogel formulations for VEGFA expressed baculovirus delivery promoting angiogenesis for wound healing and revascularization

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Complexities in coronary artery disease Revascularisation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Ms Paromita Islam

Montreal (Canada)

5 More presentations in this session

Presentation thumbnail
Guideline-directed medical therapy implementation changes after acute coronary syndrome and their effect of prognosis: insights from Japanese real-world database using a storage system
Doctor N. Akashi (Saitama, JP)
Abstract Slides Video
Presentation thumbnail
Adjustment of the SMART risk score by bioactive adrenomedullin enables a more accurate prediction of mortality in patients with ASCVD
Doctor B. Kurt (Aachen, DE)
Abstract Slides Video
Presentation thumbnail
Galectin-3 and cancer mortality in patients with suspected or known coronary artery disease: the ANOX study
Doctor H. Wada (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Detection of chronic obstructive pulmonary disease and frequency of cardiopulmonary events in patients with a significant smoking history hospitalised for acute myocardial infarction
Doctor W. Parker (Sheffield, GB)
Abstract Slides Video
Presentation thumbnail
Impaired high-density lipoprotein-associated cholesterol efflux capacity predicts coronary rapid plaque progression
Doctor S. Feng (Shanghai, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Complexities in coronary artery disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
A baculoviral gene and drug-eluting (GDES) stent to promote re-endothelialization and prevent restenosis caused by atherosclerosis.
thumbnail
Congress Presentation
Angiogenic gene therapy for refractory angina: results of the epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (EXACT) phase 2 trial
thumbnail
Congress Presentation
VasCraft: new decellularized and re-endothelialized human vascular graft produced by tissue engineering for use in arterial bypass

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources